MA52206A - Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels - Google Patents
Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturelsInfo
- Publication number
- MA52206A MA52206A MA052206A MA52206A MA52206A MA 52206 A MA52206 A MA 52206A MA 052206 A MA052206 A MA 052206A MA 52206 A MA52206 A MA 52206A MA 52206 A MA52206 A MA 52206A
- Authority
- MA
- Morocco
- Prior art keywords
- natural nkg2d
- receptors
- ligands binding
- natural
- modified domains
- Prior art date
Links
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title 2
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862648636P | 2018-03-27 | 2018-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52206A true MA52206A (fr) | 2021-02-17 |
Family
ID=66286967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052206A MA52206A (fr) | 2018-03-27 | 2019-03-27 | Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190300594A1 (fr) |
EP (1) | EP3774873A1 (fr) |
JP (2) | JP7443240B2 (fr) |
KR (1) | KR20200138311A (fr) |
CN (1) | CN112074532A (fr) |
AU (1) | AU2019243703B2 (fr) |
BR (1) | BR112020019336A2 (fr) |
CA (1) | CA3093967A1 (fr) |
CO (1) | CO2020013140A2 (fr) |
IL (1) | IL277339A (fr) |
JO (1) | JOP20200234A1 (fr) |
MA (1) | MA52206A (fr) |
MX (1) | MX2020010003A (fr) |
PH (1) | PH12020551554A1 (fr) |
SG (1) | SG11202009234QA (fr) |
WO (1) | WO2019191243A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021178896A1 (fr) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anticorps anti-glyco-cd44 et leurs utilisations |
CN111471099B (zh) * | 2020-03-31 | 2022-04-12 | 长沙学院 | MICA胞外区突变体及其筛选的方法、scFv-MICA融合抗体及其制备方法和应用 |
WO2022187591A1 (fr) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anticorps anti-glyco-cd44 et leurs utilisations |
IL307945A (en) | 2021-06-08 | 2023-12-01 | Xyphos Biosciences Inc | NKG2D antibody-ligand region fusion protein |
CN117412988A (zh) | 2021-06-08 | 2024-01-16 | 修普霍斯生物科学有限公司 | 抗体-nkg2d配体结构域融合蛋白 |
CA3228178A1 (fr) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anticorps anti-glyco-muc4 et leurs utilisations |
KR20240109604A (ko) | 2021-09-03 | 2024-07-11 | 고 테라퓨틱스, 인크. | 항-글리코-cMET 항체 및 그의 용도 |
CA3230933A1 (fr) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anticorps anti-glyco-lamp1 et leurs utilisations |
WO2024167898A1 (fr) | 2023-02-07 | 2024-08-15 | Go Therapeutics, Inc. | PROTÉINES DE FUSION D'ANTICORPS COMPRENANT DES ANTICORPS ANTI-GLYCO-MUC4 ET DES DOMAINES α1-α2 DE PROTÉINE MIC, ET LEURS UTILISATIONS |
WO2024167875A1 (fr) | 2023-02-07 | 2024-08-15 | Xyphos Biosciences Inc. | Récepteur antigénique chimérique et protéine de fusion de domaine ligand nkg2d anticorps |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
EP3331912B1 (fr) * | 2015-08-04 | 2024-05-01 | Xyphos Biosciences Inc. | Fragments d'anticorps variables et insérables et domaines a1-a2 modifiés de ligands de nkg2d, et ligands non naturels de nkg2d qui se lient à des récepteurs nkg2d non naturels |
WO2020159941A1 (fr) * | 2019-01-28 | 2020-08-06 | Xyphos Biosciences Inc. | Ligands de nkg2d non naturels modifiés administrant sélectivement des molécules hétérologues attachées à des récepteurs nkg2d non naturels sur des cellules car |
-
2019
- 2019-03-27 WO PCT/US2019/024298 patent/WO2019191243A1/fr unknown
- 2019-03-27 CA CA3093967A patent/CA3093967A1/fr active Pending
- 2019-03-27 EP EP19719671.0A patent/EP3774873A1/fr active Pending
- 2019-03-27 JO JOP/2020/0234A patent/JOP20200234A1/ar unknown
- 2019-03-27 MA MA052206A patent/MA52206A/fr unknown
- 2019-03-27 SG SG11202009234QA patent/SG11202009234QA/en unknown
- 2019-03-27 BR BR112020019336-4A patent/BR112020019336A2/pt unknown
- 2019-03-27 US US16/366,320 patent/US20190300594A1/en active Pending
- 2019-03-27 CN CN201980022711.XA patent/CN112074532A/zh active Pending
- 2019-03-27 JP JP2020551492A patent/JP7443240B2/ja active Active
- 2019-03-27 MX MX2020010003A patent/MX2020010003A/es unknown
- 2019-03-27 AU AU2019243703A patent/AU2019243703B2/en active Active
- 2019-03-27 KR KR1020207030914A patent/KR20200138311A/ko not_active Application Discontinuation
-
2020
- 2020-09-14 IL IL277339A patent/IL277339A/en unknown
- 2020-09-24 PH PH12020551554A patent/PH12020551554A1/en unknown
- 2020-10-21 CO CONC2020/0013140A patent/CO2020013140A2/es unknown
-
2023
- 2023-11-02 JP JP2023188942A patent/JP2024023230A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20190300594A1 (en) | 2019-10-03 |
PH12020551554A1 (en) | 2021-06-07 |
WO2019191243A1 (fr) | 2019-10-03 |
SG11202009234QA (en) | 2020-10-29 |
EP3774873A1 (fr) | 2021-02-17 |
BR112020019336A2 (pt) | 2021-01-05 |
CN112074532A (zh) | 2020-12-11 |
JP7443240B2 (ja) | 2024-03-05 |
IL277339A (en) | 2020-10-29 |
CO2020013140A2 (es) | 2021-01-18 |
CA3093967A1 (fr) | 2019-10-03 |
AU2019243703A1 (en) | 2020-10-08 |
MX2020010003A (es) | 2021-01-15 |
RU2020134984A (ru) | 2022-04-27 |
KR20200138311A (ko) | 2020-12-09 |
JP2024023230A (ja) | 2024-02-21 |
AU2019243703B2 (en) | 2024-07-25 |
JOP20200234A1 (ar) | 2020-09-15 |
JP2021519287A (ja) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52206A (fr) | Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels | |
MA54514A (fr) | Anticorps se liant à cd3 | |
EA201890866A1 (ru) | Связывающие молекулы, которые ингибируют рост рака | |
MA42060A (fr) | Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostate | |
DK3428274T3 (da) | Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation | |
MA49038A (fr) | Anticorps bispécifiques se liant particulièrement à pd1 et lag3 | |
MA45186A (fr) | Domaines de fibronectine de type iii se liant à l'albumine sérique | |
DK3331912T3 (da) | Indsættelige variable fragmenter af antistoffer og modificerede a1-a2-domæner af nkg2d-ligander og ikke-naturlige nkg2d-ligander, der binder ikke-naturlige nkg2d-receptorer | |
DK3242890T3 (da) | Agonistiske tnf-receptor-bindingsmidler | |
EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
MA45680A (fr) | Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 | |
MA53616A (fr) | Protéines bispécifiques modifiées | |
MA51649A (fr) | Culture de placenta pour isoler des exosomes | |
EA202091315A3 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
MA43817A (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
DK3046420T3 (da) | Forbedret fremgangsmåde til humanisering af animalsk skummetmælk | |
MA45185A (fr) | Composé de sulfonamide ou son sel | |
ES2980503T3 (es) | Material alternativo al cuero | |
SG11202101152QA (en) | Antigen-binding molecule containing two antigen-binding domains that are linked to each other | |
DK3729255T3 (da) | Mapning af entiteter til konti | |
MA51302A (fr) | Anticorps se liant à hla-a2/wt1 | |
MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
DK3830132T5 (da) | Humaniserede antistoffer mod psma | |
MA46523A (fr) | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 | |
MA53498A (fr) | Production de protéines recombinantes |